Clinical study of topical nanoliposome formulation of ruxolitinib 1.5% in treatment of eczema

Clinical study of topical nanoliposome formulation of ruxolitinib 1.5% in treatment of mild to moderate atopic dermatitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161207031288N9

Enrollment

Registered

2021-06-01

Start date

2021-06-10

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis. Atopic dermatitis

Interventions

Intervention group: Topical use of emulgel of nanoliposomes contain ruxolitinib 1.5 percent produced by lipid film hydration method in the faculty of pharmacy of Tehran university of medical sciences

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Case of mild to moderate atopic dermatitis (SCORAD between 4 and 12) Older than 18 years Signing informed consent to participate in the study Having a negative pregnancy test Willingness to actively participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Use of any topical corticosteroids in the last 14 days Drug and alcohol addiction Use of oral corticosteroids or other immunosuppressive drugs in the last 28 days

Design outcomes

Primary

Measure	Time frame
Severity of lesions of atopic dermatitis according to Scorad score. Timepoint: Before intervention, and 2 and 4 weeks after than. Method of measurement: Clinical exam.	—

Secondary

Measure	Time frame
Dermal erythema variations. Timepoint: Before intervention, and 2 and 4 weeks after than. Method of measurement: Mexameter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Firooz

Centre for Research and Training in Skin Diseases and Leprosy

dermalab@sina.tums.ac.ir+98 21 8897 2220

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026